Opportunity Information: Apply for RFA DA 10 013
Apply for RFA DA 10 013
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "2010 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (DP1)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Jan 26, 2010 and posted on Jan 26, 2010.
- Applicants must submit their applications by Jul 2, 2010. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) State governments For profit organizations other than small businesses City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Private institutions of higher education Independent school districts Special district governments Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The 2010 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (DP1), Funding Opportunity Number RFA-DA-10-013, is a National Institutes of Health (NIH) grant run by the National Institute on Drug Abuse (NIDA) to speed up the translation of research findings into real, usable medications for addiction. The core idea is to back exceptional basic and/or clinical researchers who have both the scientific ability and the practical drive to move discoveries toward treatment products, not just publishable results. NIDA frames this as an effort to make meaningful progress toward safe and effective interventions for disorders associated with tobacco, cannabis, cocaine, methamphetamine, heroin, and prescription opioid use or misuse.
The scope is explicitly medication development and can include either traditional pharmaceuticals (small-molecule drugs) or biologics. Biologics are defined broadly here, including products such as vaccines and recombinant therapeutic proteins made through biological processes. Proposed work can target a single substance use disorder or multiple disorders, and it does not have to be limited to an all-or-nothing cure; applications can focus on specific clinically important components of addiction such as withdrawal symptoms, craving, or relapse prevention. The announcement also makes room for pragmatic translational strategies, including testing new formulations of already marketed medications that were originally approved for other conditions, as well as evaluating new combinations of existing medications, as long as the goal is to develop promising treatments for addiction.
A key structural feature of this opportunity is that it ran as a two-phase competition. Investigators first had to submit a pre-application under a related announcement (PAR-10-095). Those pre-applications were reviewed by external reviewers, and only the most outstanding submissions were invited to move forward with a full application under the DP1 Funding Opportunity Announcement. Final 2010 Avant Garde awardees were selected from this invited pool, which means the DP1 stage functioned as a selective second round rather than an open submission pathway for everyone.
The funding mechanism is the NIH DP1 award, which is part of the NIH Director's Pioneer-type family of awards and is generally used to support bold, high-impact research trajectories led by highly qualified investigators. For this specific 2010 competition, NIDA anticipated committing about $2,000,000 total in fiscal year 2010, with an expected 2 to 3 awards, contingent on receiving enough applications that met the scientific and programmatic bar. There was no cost sharing or matching requirement indicated.
Eligibility was broad and included a wide range of organization types across the public, private, nonprofit, and academic sectors. Eligible applicants listed in the opportunity included state and local governments (including counties, cities, townships, special districts, and independent school districts), public and state-controlled institutions of higher education, private institutions of higher education, nonprofits (including 501(c)(3) and certain non-501(c)(3) entities), for-profit organizations (including small businesses and other for-profits), and tribal entities (federally recognized tribal governments as well as other tribal organizations). The announcement also called out additional eligible categories such as HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, tribally controlled colleges and universities, faith-based or community-based organizations, regional organizations, and U.S. territories or possessions, along with eligible federal agencies.
Administratively, the opportunity was posted January 26, 2010, with an original and current closing date of July 2, 2010, and an archive date of August 2, 2010. The CFDA program associated with it was 93.279 (Drug Abuse and Addiction Research Programs). The official full announcement was linked through the NIH grants guide at http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-10-013.html, and the contact listed for technical access or linking issues was the NIH Office of Extramural Research (OER) webmaster (FBOWebmaster@OD.NIH.GOV).
Frequently Asked Questions (FAQs)
What is the 2010 NIDA Translational Avant Garde Award (DP1)?
It is a National Institutes of Health (NIH) grant opportunity run by the National Institute on Drug Abuse (NIDA) to speed up the translation of research findings into real, usable medications for diseases of addiction. The opportunity is identified as the 2010 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (DP1).
What is the Funding Opportunity Number for this program?
The Funding Opportunity Number is RFA-DA-10-013.
What is the main goal of this funding opportunity?
The main goal is to support exceptional basic and/or clinical researchers who can move discoveries toward treatment products (medications), not only toward publishable research results. NIDA framed this as an effort to make meaningful progress toward safe and effective interventions for addiction-related disorders.
What substances or disorders does NIDA highlight in the scope?
The opportunity specifically mentions disorders associated with tobacco, cannabis, cocaine, methamphetamine, heroin, and prescription opioid use or misuse.
Is this grant focused on medication development specifically?
Yes. The scope is explicitly medication development intended to translate research findings into treatments for addiction.
What kinds of medications or therapeutic approaches are allowed?
The opportunity allows traditional pharmaceuticals (small-molecule drugs) as well as biologics.
What does NIDA mean by "biologics" in this announcement?
Biologics are defined broadly and include products such as vaccines and recombinant therapeutic proteins made through biological processes.
Can an application target more than one substance use disorder?
Yes. Proposed work can target a single disorder or multiple disorders.
Does the project have to aim for a complete cure for addiction?
No. Applications may focus on specific clinically important components of addiction, including withdrawal symptoms, craving, or relapse prevention.
Does the opportunity allow repurposing or reformulating existing medications?
Yes. The announcement includes pragmatic translational strategies such as testing new formulations of already marketed medications that were originally approved for other conditions, as long as the goal is to develop promising treatments for addiction.
Are combinations of existing medications allowed?
Yes. The opportunity allows evaluating new combinations of existing medications when the aim is to develop promising addiction treatments.
Was this an open competition for full applications?
No. It was structured as a two-phase competition. Investigators first submitted a pre-application under a related announcement (PAR-10-095). Only the most outstanding pre-applications were invited to submit a full application under the DP1 opportunity.
What is the pre-application announcement number mentioned for phase one?
The pre-application phase referenced a related announcement: PAR-10-095.
How were applicants selected to submit a full DP1 application?
Pre-applications were reviewed by external reviewers, and only the most outstanding submissions received invitations to move forward with a full application under the DP1 Funding Opportunity Announcement.
What NIH award mechanism is used for this opportunity?
The funding mechanism is the NIH DP1 award, described as part of the NIH Director's Pioneer-type family of awards and generally used to support bold, high-impact research trajectories led by highly qualified investigators.
How much funding did NIDA anticipate committing in fiscal year 2010?
NIDA anticipated committing about $2,000,000 total in fiscal year 2010 for this competition, contingent on receiving enough applications that met scientific and programmatic requirements.
How many awards were expected?
NIDA expected to make 2 to 3 awards, depending on the number and quality of applications received.
Was cost sharing or a matching requirement included?
No cost sharing or matching requirement was indicated in the provided information.
Who was eligible to apply?
Eligibility was broad and included many organization types across public, private, nonprofit, and academic sectors, as well as certain tribal entities, U.S. territories or possessions, and eligible federal agencies.
Are state and local government entities eligible?
Yes. The eligible applicant types listed include state and local governments, including counties, cities, townships, special districts, and independent school districts.
Are higher education institutions eligible?
Yes. Both public/state-controlled institutions of higher education and private institutions of higher education were listed as eligible.
Are nonprofit organizations eligible?
Yes. Eligible applicants included nonprofits with 501(c)(3) status and certain nonprofits without 501(c)(3) status.
Are for-profit organizations eligible?
Yes. For-profit organizations were listed as eligible, including small businesses and other for-profits.
Are tribal governments and tribal organizations eligible?
Yes. Eligible applicants included federally recognized tribal governments and other tribal organizations.
Were specific institution categories called out as eligible?
Yes. The announcement explicitly called out additional eligible categories such as HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, tribally controlled colleges and universities, faith-based or community-based organizations, regional organizations, and U.S. territories or possessions, along with eligible federal agencies.
What is the CFDA number associated with this opportunity?
The CFDA program associated with this opportunity is 93.279 (Drug Abuse and Addiction Research Programs).
When was the opportunity posted?
It was posted on January 26, 2010.
What was the closing date for applications?
The original and current closing date provided was July 2, 2010.
When was the opportunity archived?
The archive date provided was August 2, 2010.
Where can the official full announcement be found?
The official full announcement was linked through the NIH Grants Guide at: http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-10-013.html
Who is the contact for technical access or linking issues?
The contact listed for technical access or linking issues was the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Education Health
Next opportunity: Global Undergraduate Exchange Program for Pakistan
Previous opportunity: Pre Application for the 2010 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (X02)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 10 013
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 10 013) also looked into and applied for these:
| Funding Opportunity |
|---|
| Medications Development for Substance Related Disorders (R01) Apply for RFA DA 10 018 Funding Number: RFA DA 10 018 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Deep Sequencing and Analysis of Pharmacogenomic Regions Discovery and Analysis of Genetic Variants Contributing to Drug Abuse and Addiction (R01) Apply for RFA DA 10 019 Funding Number: RFA DA 10 019 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Institutional Clinical and Translational Science Award (U54) Apply for RFA RM 10 001 Funding Number: RFA RM 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Technology Based Adherence Interventions for Substance Abusing Populations with HIV (R01) Apply for PAS 10 097 Funding Number: PAS 10 097 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Technology Based Adherence Interventions for Substance Abusing Populations with HIV (R34) Apply for PAS 10 098 Funding Number: PAS 10 098 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Chronic Co Morbid Conditions in HIV U.S. Adults on Highly Effective Anti Retroviral Therapy (R01) Apply for RFA NR 10 001 Funding Number: RFA NR 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Chronic Co Morbid Conditions in HIV U.S. Adults on Highly Effective Anti Retroviral Therapy (R21) Apply for RFA NR 10 002 Funding Number: RFA NR 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (Parent F31) Apply for PA 10 108 Funding Number: PA 10 108 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Comprehensive Partnerships to Reduce Cancer Health Disparities (Limited Competition U54) Apply for RFA CA 10 503 Funding Number: RFA CA 10 503 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Palliative Care Research for Children Facing Life Limiting Conditions (R21) Apply for RFA NR 10 007 Funding Number: RFA NR 10 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Palliative Care Research for Children Facing Life Limiting Conditions (R01) Apply for RFA NR 10 006 Funding Number: RFA NR 10 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Common Pathogenetic Mechanisms of Lung Cancer and COPD (R01) Apply for RFA HL 11 002 Funding Number: RFA HL 11 002 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Collaborative Clinical Trials in Drug Abuse (Collaborative R01) Apply for PAR 10 099 Funding Number: PAR 10 099 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Strategic Partnering to Evaluate Cancer Signatures SPECS II (U01) Apply for PAR 10 126 Funding Number: PAR 10 126 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Epigenetic Factors Associated with Symptoms and Complications of Chronic Disorders (Competitive Revision R01) Apply for RFA NR 10 005 Funding Number: RFA NR 10 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Epigenetic Factors Associated with Symptoms and Complications of Chronic Disorders (R01) Apply for RFA NR 10 004 Funding Number: RFA NR 10 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R03) Apply for PA 10 131 Funding Number: PA 10 131 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R01) Apply for PA 10 129 Funding Number: PA 10 129 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R21) Apply for PA 10 130 Funding Number: PA 10 130 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| The Medical Education Partnership Initiative (MEPI) (R24) Apply for RFA TW 10 008 Funding Number: RFA TW 10 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 10 013", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.